Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...

Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT developer OpenAI ...